Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
Kaitlyn K.H. Goey(Utrecht University), Miriam Koopman(Utrecht University), John Zalcberg(Monash Health), Cathy Eng(Vanderbilt University), Alberto Sobrero(Ospedale Policlinico San Martino), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Christopher H. Lieu(University of Colorado Denver), Howard S. Höchster(Rutgers, The State University of New Jersey), Richard Adams(Velindre Cancer Centre), Halfdan Sørbye(Haukeland University Hospital), Volker Heinemann(LMU Klinikum), Richard L. Schilsky(American Society of Clinical Oncology), G. Bodoky(Unified Szent István and Szent László Hospital), Jordan Berlin(Dana-Farber Cancer Institute), Cornelis J.A. Punt(Utrecht University), Qian Shi(Mayo Clinic), Dirk Arnold(Asklepios Klinik Altona), Neal J. Meropol(Flatiron Health (United States)), Richard Kaplan(University College London), Aimery de Gramont(Institut Hospitalier Franco Britannique), Bengt Glimelius(Uppsala University), Axel Grothey(Campbell Clinic), Timothy Price(Basil Hetzel Institute), Einat Shacham‐Shmueli(Sheba Medical Center), John Souglakos(University of Crete), Thierry André(Inserm), Roberto Labianca(Ospedale Papa Giovanni XXIII), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Martijn G.H. van Oijen(Amsterdam UMC Location University of Amsterdam), Eduardo Díaz‐Rubio(Hospital Clínico San Carlos)
Cited by 34
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k